OPEN

Author Correction: Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase

David F. Thieker¹, Yongmei Xu, Digantkumar Chapla, Chelsea Nora, Hong Qiu, Thomas Felix, Lianchun Wang², Kelley W. Moremen³, Jian Liu, Jeffrey D. Esko⁴ & Robert J. Woods

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-018-29602-4>, published online 07 August 2018

In this Article, the authors neglected to include some potential conflicts of interest.

The Competing Interests section should read:

“J. L. is a founder of Glycan Therapeutics. D.F.T., Y.X., D.K., C.N., T.F., H.Q., L.W., K.W.M., R.J.W. declare no competing interests. J.D.E. is a co-founder of TEGA Therapeutics. J.D.E. and The Regents of the University of California have licensed a University invention to and have an equity interest in TEGA Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.”

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

Published online: 09 June 2020